82 related articles for article (PubMed ID: 16342159)
1. Assessment of dynamic susceptibility contrast cerebral blood flow response to amphetamine challenge: a human pharmacological magnetic resonance imaging study at 1.5 and 4 T.
Rose SE; Janke AL; Strudwick MW; McMahon KL; Chalk JB; Snyder P; De zubicaray GI
Magn Reson Med; 2006 Jan; 55(1):9-15. PubMed ID: 16342159
[TBL] [Abstract][Full Text] [Related]
2. Cortical responses to amphetamine exposure studied by pCASL MRI and pharmacokinetic/pharmacodynamic dose modeling.
Nordin LE; Li TQ; Brogren J; Johansson P; Sjögren N; Hannesdottir K; Björk C; Segerdahl M; Wang DJ; Julin P
Neuroimage; 2013 Mar; 68():75-82. PubMed ID: 23246855
[TBL] [Abstract][Full Text] [Related]
3. Application of a superparamagnetic iron oxide (Resovist) for MR imaging of human cerebral blood volume.
Reimer P; Schuierer G; Balzer T; Peters PE
Magn Reson Med; 1995 Nov; 34(5):694-7. PubMed ID: 8544689
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of combining sequentially acquired gadobenate dimeglumine-enhanced magnetic resonance imaging and resovist-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: comparison with computed tomography hepatic arteriography and computed tomography arterioportography using 16-slice multidetector computed tomography.
Kim YK; Kwak HS; Han YM; Kim CS
J Comput Assist Tomogr; 2007; 31(5):702-11. PubMed ID: 17895780
[TBL] [Abstract][Full Text] [Related]
5. [T1-weighted dynamic MRI with new superparamagnetic iron oxide particles (Resovist): results of a phantom study as well as 25 patients].
Müller M; Reimer P; Wiedermann D; Allkemper T; Marx C; Tombach B; Rummeny EJ; Shamsi K; Balzer T; Peters PE
Rofo; 1998 Mar; 168(3):228-36. PubMed ID: 9551108
[TBL] [Abstract][Full Text] [Related]
6. Bicuculline-induced brain activation in mice detected by functional magnetic resonance imaging.
Mueggler T; Baumann D; Rausch M; Rudin M
Magn Reson Med; 2001 Aug; 46(2):292-8. PubMed ID: 11477632
[TBL] [Abstract][Full Text] [Related]
7. [Dynamic and static MRI using superparamagnetic MRI contrast medium Resovist for visualizing primary and secondary liver tumors].
Vogl TJ; Schwarz W; Hammerstingl R; Kümmel S; Balzer JO; Mack MG; Diebold T; Balzer T; Shamsi K; Bechstein WO; Schrem H; Neuhaus P; Felix R
Rofo; 1997 Sep; 167(3):264-73. PubMed ID: 9376555
[TBL] [Abstract][Full Text] [Related]
8. [Use of SPIO-enhanced T1- and T2-weighted images for the differentiation of liver lesions: an ROC analysis].
Stroszczynski C; Gaffke G; Gretschel S; Rambow A; Jost D; Schlecht I; Schneider U; Schicke B; Hohenberger P; Gebauer B; Felix R
Rofo; 2003 Oct; 175(10):1368-75. PubMed ID: 14556106
[TBL] [Abstract][Full Text] [Related]
9. Quantifying the blood oxygenation level dependent effect in cerebral blood volume-weighted functional MRI at 9.4T.
Lu H; Scholl CA; Zuo Y; Stein EA; Yang Y
Magn Reson Med; 2007 Sep; 58(3):616-21. PubMed ID: 17763339
[TBL] [Abstract][Full Text] [Related]
10. Sensitive physiologic imaging with contrast-enhanced magnetic resonance imaging.
Litt L
Anesthesiology; 1998 Apr; 88(4):847-50. PubMed ID: 9579490
[No Abstract] [Full Text] [Related]
11. Central nervous system inflammatory response after cerebral infarction as detected by magnetic resonance imaging.
Saleh A; Wiedermann D; Schroeter M; Jonkmanns C; Jander S; Hoehn M
NMR Biomed; 2004 Jun; 17(4):163-9. PubMed ID: 15229929
[TBL] [Abstract][Full Text] [Related]
12. MRI findings of focal eosinophilic liver diseases.
Kim YK; Kim CS; Moon WS; Cho BH; Lee SY; Lee JM
AJR Am J Roentgenol; 2005 May; 184(5):1541-8. PubMed ID: 15855113
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility contrast magnetic resonance imaging determination of fractional tumor blood volume: a noninvasive imaging biomarker of response to the vascular disrupting agent ZD6126.
Robinson SP; Howe FA; Griffiths JR; Ryan AJ; Waterton JC
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):872-9. PubMed ID: 17889267
[TBL] [Abstract][Full Text] [Related]
14. The role of SPIO-enhanced MRI in the detection of malignant liver lesions.
Savranoglu P; Obuz F; Karasu S; Coker A; Secil M; Sagol O; Igci E; Dicle O; Astarcioglu I
Clin Imaging; 2006; 30(6):377-81. PubMed ID: 17101405
[TBL] [Abstract][Full Text] [Related]
15. Functional MRI using intravascular contrast agents: detrending of the relative cerebrovascular (rCBV) time course.
Schwarz AJ; Reese T; Gozzi A; Bifone A
Magn Reson Imaging; 2003 Dec; 21(10):1191-200. PubMed ID: 14725926
[TBL] [Abstract][Full Text] [Related]
16. Quantification of renal perfusion using an intravascular contrast agent (part 1): results in a canine model.
Aumann S; Schoenberg SO; Just A; Briley-Saebo K; Bjørnerud A; Bock M; Brix G
Magn Reson Med; 2003 Feb; 49(2):276-87. PubMed ID: 12541248
[TBL] [Abstract][Full Text] [Related]
17. [Iron-oxide-enhanced MR imaging of inflammatory atherosclerotic lesions: overview of experimental and initial clinical results].
Schmitz SA
Rofo; 2003 Apr; 175(4):469-76. PubMed ID: 12677500
[TBL] [Abstract][Full Text] [Related]
18. [Focal nodular hyperplasia of the liver: imaging findings with emphasis on the findings of superparamagnetic iron oxide-enhanced MR imaging].
Han JK; Kim SH
Korean J Hepatol; 2006 Mar; 12(1):116-9. PubMed ID: 16565614
[No Abstract] [Full Text] [Related]
19. How can superparamagnetic iron oxides be used to monitor disease and treatment?
Unger EC
Radiology; 2003 Dec; 229(3):615-6. PubMed ID: 14657295
[No Abstract] [Full Text] [Related]
20. T1 effects of a bolus-injectable superparamagnetic iron oxide, SH U 555 A: dependence on field strength and plasma concentration--preliminary clinical experience with dynamic T1-weighted MR imaging.
Reimer P; Müller M; Marx C; Wiedermann D; Muller R; Rummeny EJ; Ebert W; Shamsi K; Peters PE
Radiology; 1998 Dec; 209(3):831-6. PubMed ID: 9844683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
